Spinal Muscular Atrophy Treatment Market Expected To Reach $10.37 Billion By 2030 As Growth Accelerates At 15.2% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Spinal Muscular Atrophy Treatment Market Value Expansion And Long-Term Growth Outlook
The spinal muscular atrophy treatment market has experienced significant expansion in recent years. Its value is projected to increase from $5.1 billion in 2025 to $5.89 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.5%. Historical growth was driven by factors such as the scarcity of treatment alternatives for SMA, limited public understanding of genetic conditions, a dependence on hospital-centered care, a gradual uptake of advanced therapies, and insufficient early diagnostic initiatives.
The market for spinal muscular atrophy treatments is projected to experience substantial expansion in the coming years, reaching $10.38 billion by 2030 with a compound annual growth rate of 15.2%. This upward trajectory in the forecast period is driven by the development of advanced gene therapies, increased funding for SMA research, the expansion of newborn screening initiatives, and the growth of specialized clinics and homecare services, alongside the incorporation of digital health and telemedicine solutions. Key trends influencing the period include the growing use of gene therapy and SMN2-targeting treatments, a stronger emphasis on early detection and universal newborn screening, the rise of homecare and specialty clinic-based SMA management, the development of multidisciplinary care teams for patients, and the adoption of telehealth and remote monitoring technologies.
Download A Free Sample Report For Comprehensive Market Insights:
Spinal Muscular Atrophy Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated expansion of the spinal muscular atrophy treatment market is being driven by an intensified emphasis on gene therapy. This medical method entails altering a person’s genetic code—either DNA or RNA—to address or avert illnesses. This heightened attention on gene therapy stems largely from its capacity to tackle the fundamental causes of genetic disorders by directly correcting or substituting defective genes, thereby providing enduring or permanent therapeutic benefits that surpass those of conventional approaches. Treatments for spinal muscular atrophy, like onasemnogene abeparvovec (Zolgensma), effectively leverage gene therapy through a single-dose, precision-focused strategy that introduces a working version of the SMN1 gene, substantially enhancing motor abilities and life quality for SMA patients. As an example, reports from the American Society of Gene and Cell Therapy, a US-based entity dedicated to gene and cell therapy, indicate that by January 2024, there was a 10% rise in Phase III gene therapy trials during the fourth quarter of 2023 compared to the prior quarter—the first such uptick observed since the third quarter of 2022. Consequently, this increasing concentration on gene therapy is fueling the momentum behind the spinal muscular atrophy treatment market.
Spinal Muscular Atrophy Treatment Market Segment Analysis Highlighting Growth Areas
The spinal muscular atrophy treatment market covered in this report is segmented –
1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments
2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications
2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises
3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy
4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy
Spinal Muscular Atrophy Treatment Market Trends: What Is Shaping Future Industry Growth?
Leading market players in the spinal muscular atrophy treatment sector are concentrating on creating advanced formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, aimed at boosting motor function and decelerating disease advancement. These tablets, which are taken orally, work by altering the splicing of the SMN2 gene to promote the production of functional SMN protein, essential for preserving motor neurons. By elevating levels of full-length SMN protein, they assist in treating spinal muscular atrophy (SMA), leading to enhanced muscle function and a slower progression of the condition. A notable example occurred in February 2025 when Genentech, Inc., a biotechnology firm based in the United States, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet. This represents the first non-invasive SMN2 splicing modifier tablet specifically designed for SMA management. The Evrysdi tablet delivers effectiveness and safety comparable to the current oral solution, while offering extra advantages like the ability to be stored at room temperature and easier administration for patients aged 2 years and older weighing over 44 lbs (20 kgs), thereby improving convenience and adaptability in disease control.
Spinal Muscular Atrophy Treatment Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED
Access The Complete Spinal Muscular Atrophy Treatment Market Report:
Spinal Muscular Atrophy Treatment Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
